JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study.
Amandine GouverneurJerome AvouacClément PratiJean-Luc CracowskiThierry SchaeverbekeAntoine ParienteMarie-Elise TruchetetPublished in: European journal of clinical pharmacology (2022)
This study shows evidence of an increased risk of VTE and ATE associated with the use of baricitinib and tofacitinib.